6VWU

X-ray structure of ALKS 4230, a fusion of circularly permuted human Interleukin-2 and Interleukin-2 Receptor alpha


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.40 Å
  • R-Value Free: 0.297 
  • R-Value Work: 0.275 
  • R-Value Observed: 0.277 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.

Lopes, J.E.Fisher, J.L.Flick, H.L.Wang, C.Sun, L.Ernstoff, M.S.Alvarez, J.C.Losey, H.C.

(2020) J Immunother Cancer 8

  • DOI: 10.1136/jitc-2020-000673
  • Primary Citation of Related Structures:  
    6VWU

  • PubMed Abstract: 
  • Interleukin-2 (IL-2) plays a pivotal role in immune homeostasis due to its ability to stimulate numerous lymphocyte subsets including natural killer (NK) cells, effector CD4 + and CD8 + T cells, and regulatory T cells (T regs ...

    Interleukin-2 (IL-2) plays a pivotal role in immune homeostasis due to its ability to stimulate numerous lymphocyte subsets including natural killer (NK) cells, effector CD4 + and CD8 + T cells, and regulatory T cells (T regs ). Low concentrations of IL-2 induce signaling through the high-affinity IL-2 receptor (IL-2R) comprised of IL-2Rα, IL-2Rβ, and common γ chain (γ c ), preferentially expressed on T regs . Higher concentrations of IL-2 are necessary to induce signaling through the intermediate-affinity IL-2R, composed of IL-2Rβ and γ c , expressed on memory CD8 + T cells and NK cells. Recombinant human IL-2 (rhIL-2) is approved for treatment of metastatic melanoma and renal cell carcinoma (RCC), but adverse events including capillary leak syndrome, potentially mediated through interaction with the high-affinity IL-2R, limit its therapeutic use. Furthermore, antitumor efficacy of IL-2 may also be limited by preferential expansion of immunosuppressive T regs . ALKS 4230 is an engineered fusion protein comprised of a circularly-permuted IL-2 with the extracellular domain of IL-2Rα, designed to selectively activate effector lymphocytes bearing the intermediate-affinity IL-2R.


    Organizational Affiliation

    Research, Alkermes, Inc, Waltham, Massachusetts, USA Heather.Losey@alkermes.com.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Interleukin-2,Interleukin-2 receptor subunit alpha A303Homo sapiensMutation(s): 0 
Gene Names: IL2IL2RA
Find proteins for P01589 (Homo sapiens)
Explore P01589 
Go to UniProtKB:  P01589
NIH Common Fund Data Resources
PHAROS:  P01589
Find proteins for P60568 (Homo sapiens)
Explore P60568 
Go to UniProtKB:  P60568
NIH Common Fund Data Resources
PHAROS:  P60568
Protein Feature View
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.40 Å
  • R-Value Free: 0.297 
  • R-Value Work: 0.275 
  • R-Value Observed: 0.277 
  • Space Group: P 32 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 86.809α = 90
b = 86.809β = 90
c = 119.576γ = 120
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
Aimlessdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2020-02-20 
  • Released Date: 2020-04-29 
  • Deposition Author(s): Losey, H.C.

Revision History 

  • Version 1.0: 2020-04-29
    Type: Initial release
  • Version 1.1: 2020-05-06
    Changes: Database references